Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma

Cancer

Volumn 104, Issue 12, 2005, Pages 2753-2758

  Cho, Jae Yong ^a   Paik, Yong Han ^a   Chang, Yoon Soo ^a   Lee, Se Joon ^a   Lee, Dong Ki ^a   Song, Si Young ^a   Chung, Jae Bock ^a   Park, Mi Suk ^a   Yu, Jeong Sik ^a   Yoon, Dong Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biliary tract carcinoma; Capecitabine; Gemcitabine; Phase II trial

Indexed keywords

CAPECITABINE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOLOGY; DIARRHEA; DRUG SAFETY; FEMALE; FEVER; GALLBLADDER CARCINOMA; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; ADVERSE OUTCOME; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LOCALIZATION; VOMITING; WEAKNESS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; BIOPSY, NEEDLE; BONE NEOPLASMS; CARCINOMA, DUCTAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 29144480045     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21591     Document Type: Article

References (26)

1. Wanebo HJ, Castle WN, Fechner RE. Is cancer of the gall-bladder a curable lesion? Ann Surg. 1982;195:624-631.
2. Oertli D, Herzog U, Tondelli P. Primary carcinoma of the gallbladder: operative experience during a 16-year period. Eur J Surg. 1993,159:415-420.
3. Alexander F, Rossi RL, O'Bryan M, Khettry U, Braasch JW, Watkins E Jr. Biliary carcinoma. A review of 109 cases. Am J Surg. 1984;147:503-509.
4. Wade TP, Prasad CN, Virgo KS, Johnson FE. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol 1997;64:242-245.
5. Falkson G, Macintyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984:54:965-969.
6. Takada T, Kato H, Matsushiro T, Nimura Y, Nagakawa T, Nakayama T. Combination of 5-fluorouracil, doxorubicin and mitomycin C with 5-fluorouracil alone in the treatment of pancreatic-biliary carcinomas. Oncology. 1994;51:396-400.
7. Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors. Proc Am Soc Clin Oncol 1997;16:226a (Abstr 795).
8. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
9. Budman DR, Meropol NJ, Reigner B, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin Oncol. 1998;16:1795-1802.
10. Mackean MJ, Planting AS, Twelves C, et al. Phase I and pharmacological study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977-2985.
11. Raderer M, Hejna MH, Valencak JB, et al. Two consecutive Phase II studies of 5-FU/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999;56:177-180.
12. Gallardo JO, Rubio B, Fodor M, et al. A Phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2001;12:1403-1406.
13. Dragovich T, Ramanathan R, Remick S, et al. Phase II trial of a weekly 150-minute gemcitabine infusion in patients with biliary tree carcinomas. Proc Am Soc Clin Oncol. 2000;19:264a (Abstr 1159).
14. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M. A Phase II study of gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48:783-789.
15. Penz M, Kornek GV, Raderer M, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol. 2001;12:183-186.
16. Schulz L, Schalhorn A, Wilmanns W, Heinemann V. Synergistic interaction of gemcitabine and 5-fluorouracil in colon cancer cells. Proc Am Soc Clin Oncol. 1998;17:215a (Abstr 965).
17. Hidalgo M, Castellano D, Pas-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 1999;17:585-592.
18. World Health Organization. Handbook for reporting results of cancer treatment. Publication No. 48. Geneva, Switzerland: World Health Organization, 1979.
19. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase 111 trials. Br J Cancer. 2004;90:1190-1197.
20. Fleming TR. One-sample multiple testing procedure for Phase II clinical trials. Biometrics. 1982;38:143-151.
21. Knox J, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 2004;15:770-74.
22. Gebbia V, Giuliani F, Maiello E, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter Phase II study. J Clin Oncol. 2001;19:4089-4091.
23. Kim TW, Chang HM, Kang HJ, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol. 2003;14:1115-1120.
24. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9:653-656.
25. Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343.
26. Taieb J, Mitry E, Boige V, et al. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma. Ann Oncol. 2002;13:1192-1196.